Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer

NCT07271992 is registered in ClinicalTrials.gov with First Hospital of China Medical University as lead sponsor.

NCT NCT07271992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07271992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer
Lead sponsor
First Hospital of China Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 15, 2025
Completion date
December 14, 2031
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

tnbc, triple negative breast cancer